Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167148 | 0.79 | AXL (0.41) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL11888031 | 0.76 | AXL (0.38) | AXLNUDT1BRD4APP | |
| SCHEMBL31283256 | 0.75 | AXL (0.41) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL6929283 | 0.75 | CCR1 (0.50) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL23429681 | 0.74 | MAPT (0.35) | MAPK1CCR4 | |
| SCHEMBL10130905 | 0.74 | AXL (0.37) | AXLNUDT1BRD4APPMAPK1 | |
| SCHEMBL5925823 | 0.74 | AXL (0.37) | AXLNUDT1BRD4APP | |
| SCHEMBL18937795 | 0.74 | MAPK1 (0.42) | AXLNUDT1APPMAPK1 | |
| Hydrochloric Acid SCHEMBL4976930 | 0.73 | AXL (0.39) | AXLNUDT1BRD4APP | |
| SCHEMBL18744848 | 0.73 | PAK4 (0.36) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210254000-A1 | PROCESS FOR PRODUCING A T CELL COMPOSITION | JUNO THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947216-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-9555033-B2 | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947216-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | AXL 556/4885NUDT1 1533/4885BRD4 103/4885 |
| US-20210254000-A1 | PROCESS FOR PRODUCING A T CELL COMPOSITION | ICOS, CD4, NFATC1 | AXL 402/4885NUDT1 4486/4885BRD4 4071/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | AXL 1476/4885NUDT1 2217/4885BRD4 741/4885 |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | AXL 718/4885NUDT1 1004/4885BRD4 2471/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | AXL 4640/4885NUDT1 967/4885BRD4 880/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | AXL 4640/4885NUDT1 967/4885BRD4 880/4885 |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | AXL 718/4885NUDT1 1004/4885BRD4 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.